Form 4: Stoke Therapeutics' Chief Medical Officer, Barry Ticho, Executes Stock Option and Sells Shares

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 1, 2024, Barry Ticho, the Chief Medical Officer of Stoke Therapeutics, exercised a stock option to acquire 442 shares of common stock at a price of $0.60 per share.
• On the same day, Ticho sold 9,426 shares of common stock at a weighted average price of $13.2277 per share, with individual sales ranging from $12.62 to $13.55.
• Following these transactions, Ticho directly owns 2,485 shares of common stock and holds options for 80,000 shares.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on September 14, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine transactions under a pre-arranged trading plan. There's no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned and not based on insider information.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and potential future performance of the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the transactions mitigates concerns about insider information.

Key Dates